BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34534280)

  • 1. Metabolomic identification of α-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease.
    Subburaj D; Ng B; Kariminia A; Abdossamadi S; Lauener M; Nemecek ER; Rozmus J; Kharbanda S; Kitko CL; Lewis VA; Schechter-Finklestein T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Coulter D; Chewning JH; Joyce M; Pawlowska AB; Megason GC; Lawitschka A; Ostroumov E; Klein Geltink R; Cuvelier GDE; Schultz KR
    Blood; 2022 Jan; 139(2):287-299. PubMed ID: 34534280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies.
    Schultz KR; Kariminia A; Ng B; Abdossamadi S; Lauener M; Nemecek ER; Wahlstrom JT; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Flower A; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savasan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; Azadpour S; Ostroumov E; Subrt P; Halevy A; Mostafavi S; Cuvelier GDE
    Blood; 2020 Apr; 135(15):1287-1298. PubMed ID: 32047896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating cell-free mitochondrial DNA as a diagnostic and prognostic biomarker in chronic and late acute graft-versus-host disease in children.
    Azadpour S; Abdossamadi S; Ng B; Ostroumov E; Abroun S; Cuvelier GDE; Schultz KR
    Exp Hematol; 2023 May; 121():12-17. PubMed ID: 36868452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE/PBMTC 1202 study.
    Cuvelier GDE; Ng B; Abdossamadi S; Nemecek ER; Melton A; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; Ostroumov E; Schultz KR
    Blood Adv; 2023 Jul; 7(14):3612-3623. PubMed ID: 36219586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.
    Cuvelier GDE; Nemecek ER; Wahlstrom JT; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Flower A; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; West LJ; Pan B; Al Hamarneh YN; Halevy A; Schultz KR
    Blood; 2019 Jul; 134(3):304-316. PubMed ID: 31043425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late-Onset Acute and Chronic Graft-versus-Host Disease in Children: Clinical Features and Response to Therapy.
    Takahashi T; Arora M; Okoev G; DeFor TE; Weisdorf DJ; MacMillan ML
    Transplant Cell Ther; 2021 Aug; 27(8):667.e1-667.e5. PubMed ID: 34077812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.
    Lazaryan A; Weisdorf DJ; DeFor T; Brunstein CG; MacMillan ML; Bejanyan N; Holtan S; Blazar BR; Wagner JE; Arora M
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):134-40. PubMed ID: 26365153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of graft-versus-host disease on relapse and survival in 100 patients after allogeneic hematopoietic stem cell transplantation].
    Deng XR; Ren HY; Cen XN; Wang LH; Liang ZY; Wang WS; Qiu ZX; Ou JP; Xu WL; Wang MJ; Li Y; Yin Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):994-8. PubMed ID: 19698246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.
    Weisdorf D; Zhang MJ; Arora M; Horowitz MM; Rizzo JD; Eapen M
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1727-33. PubMed ID: 22766220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia.
    Lv M; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X; Mo X
    Front Med; 2019 Dec; 13(6):667-679. PubMed ID: 31512033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program.
    Yang F; Lu D; Hu Y; Huang X; Huang H; Chen J; Wu D; Wang J; Wang C; Han M; Chen H
    Ann Transplant; 2017 Jun; 22():384-401. PubMed ID: 28652564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
    Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.
    Fujii H; Cuvelier G; She K; Aslanian S; Shimizu H; Kariminia A; Krailo M; Chen Z; McMaster R; Bergman A; Goldman F; Grupp SA; Wall DA; Gilman AL; Schultz KR
    Blood; 2008 Mar; 111(6):3276-85. PubMed ID: 17925486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia.
    Gratwohl A; Brand R; Apperley J; Biezen Av Av; Bandini G; Devergie A; Schattenberg A; Frassoni F; Guglielmi C; Iacobelli S; Michallet M; Kolb HJ; Ruutu T; Niederwieser D;
    Blood; 2002 Dec; 100(12):3877-86. PubMed ID: 12433695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Breath Washout Testing to Identify Pulmonary Chronic Graft Versus Host Disease in Children After Hematopoietic Stem Cell Transplantation.
    Rayment JH; Sandoval RA; Roden JP; Schultz KR
    Transplant Cell Ther; 2022 Jun; 28(6):328.e1-328.e7. PubMed ID: 35139399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and prognostic role of elafin in skin acute graft versus host disease: a systematic review.
    Bhattarai A; Shah S; Yadav R; Dhakal G; Neupane R; Paudel S; Bhandari P; Abu Serhan H; Sah R; Sah S; Barboza JJ
    Hematology; 2024 Dec; 29(1):2293497. PubMed ID: 38112182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentraxin-3 levels in graft-versus-host disease during allogeneic hematopoietic stem cell transplantation.
    Doehn JM; Winkler A; Kuzmina Z; Hladik A; Greinix H; Knapp S; Robak O
    Exp Hematol; 2016 Oct; 44(10):917-23. PubMed ID: 27403536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Institutes of Health-Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution.
    Lawitschka A; Gueclue ED; Januszko A; Körmöczi U; Rottal A; Fritsch G; Bauer D; Peters C; Greinix HT; Pickl WF; Kuzmina Z
    Front Immunol; 2019; 10():1879. PubMed ID: 31507582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes.
    Cho BS; Lee SE; Song HH; Lee JH; Yahng SA; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1136-43. PubMed ID: 22261380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.